Coxibs and cardiovascular disease

被引：679

作者：

FitzGerald, GA ^{[1
]}

机构：

[1] Univ Penn, Inst Translat Med & Therapeut, Philadelphia, PA 19104 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2004年 / 351卷 / 17期

关键词：

D O I：

10.1056/NEJMp048288

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

收藏

页码：1709 / 1711

页数：3

相关论文

共 5 条

[1] Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial
Farkouh, ME
Kirshner, H
Harrington, RA
Ruland, S
Verheugt, FW
Schnitzer, T
Burmester, GR
Mysler, E
Hochberg, MC
Doherty, M
Ehrsam, E
Gitton, X
Krammer, G
Mellein, B
Gimona, A
Matchaba, P
Hawkey, CJ
Chesebro, JH
[J]. LANCET, 2004, 364 (9435) : 675 - 684
[2] COX-2 and beyond: Approaches to prostaglandin inhibition in human disease
FitzGerald, G
[J]. NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (11) : 879 - 890
[3] Drug therapy: The coxibs, selective inhibitors of cyclooxygenase-2.
FitzGerald, GA
Patrono, C
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (06) : 433 - 442
[4] COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease
Ray, WA
Stein, CM
Daugherty, JR
Hall, K
Arbogast, PG
Griffin, MR
[J]. LANCET, 2002, 360 (9339) : 1071 - 1073
[5] Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial
Schnitzer, TJ
Burmester, GR
Mysler, E
Hochberg, MC
Doherty, M
Ehrsam, E
Gitton, X
Krammer, G
Mellein, B
Matchaba, P
Gimona, A
Hawkey, CJ
[J]. LANCET, 2004, 364 (9435) : 665 - 674